79 research outputs found
WAT ALTERATIONS IN DIABETIC MICE: ITS CONNECTION AND IMPLICATION IN AD PATHOGENESIS
Alzheimer’s disease (AD) is a complex disorder and multiple cellular and molecular mechanisms are involved in AD onset
and progression. Recent evidences have suggested that metabolic alterations are an important pathological feature in
disease progression in AD. Likewise, diabetes and obesity, two mayor metabolic illnesses associated with white adipose
tissue expansion, are risk factors for AD. Here, we hypothesize that the white adipose tissue may serve as a key communicator organ between the brain and peripheral metabolic illnesses. We used histological stains,
immunohistochemistry and biochemical means to determine changes in the white adipose tissue from WT and db/db mice.
Moreover, similar techniques were used in the brain of 3xTg-AD mice that received white fat pads from WT and db/db donors to determine any changes in amyloid and tau pathology. Our study shows that recipient 3xTg-AD mice from db/db fat pads mice develop profound changes in tau pathology due to increased CDK5/p25 expression compared to 3xTg-AD mice that
received fad pads from WT mice. This increment in tau level was associated with elevated levels in IL-1β and microglial activation. However, we found that Aβ levels were reduced in recipient 3xTg-AD mice from db/db fat pads compared to 3xTg-
AD mice that received fad pads from WT mice. These reduction in Aβ levels were correlated with an increment in microglia
phagocytic capacity. Overall, our study demonstrates a novel important crosstalk between AD and diabetes type II through white adipose cells and a differential effect on tau and Aβ pathology
Pleuroparenchymal Fibroelastosis : a New Entity within the Spectrum of Rare Idiopathic Interstitial Pneumonias
Pleuroparenchymal fibroelastosis (PPFE) is a rare entity that has been recently included in the official American Thoracic Society/European Respiratory Society (ATS/ERS) statement in 2013 as a group of rare idiopathic interstitial pneumonias (IIPs). PPFE is characterized by pleural and subpleural parenchymal thickening due to elastic fiber proliferation, mainly in the upper lobes. The etiology of the disease is unclear, although some cases have been associated as a complication after bone marrow transplantation, lung transplantation (LT), chemotherapy, and recurrent respiratory infections. The patients usually report progressive dyspnea and dry cough and are predisposed to develop spontaneous or iatrogenic pneumothoraces after surgical lung biopsy (SLB) for its diagnosis. That is why better awareness with the clinical and radiologic features can help optimal management by the multidisciplinary team. Novel invasive techniques such as cryobiopsy may become useful tools in these patients as it could spare SLB. We present the first reported cases in Spain
Human amyloid seeds aggregate more efficient than seeds from old 3xtg-ad mice
Aims: Most age-associated neurodegenerative disorders involve the aggregation of specific proteins within the nervous system, as occurs in Alzheimer’s disease (AD). Recent evidence indicates that Aβ can misfold and aggregate into seeds that structurally corrupt native proteins, mimicking a prion-like process of template protein corruption or seeding. In fact, studies in animal models show that the injection of brain homogenates from AD patients or from aged APP-transgenic mice containing Aβ aggregates, can induce some of the neuropathological hallmarks of AD. However, it is still unknown which Aβ-misfolded species are most efficient in triggering the aggregation process. Here, we seek to perform a comparative study to determine whether Aβ seeds from humans vs a familial AD line (the 3xTg-AD model) is more efficient to generate amyloid aggregates. Methods: We employed histological and molecular approaches to determine amyloid level, species and aggregative capacity of brain homogenates from an AD patient (stage C for amyloid, from the Alzheimer’s Disease Research Center at UCI) vs old-3xTg-AD mice (25-month-old). Such brain homogenates were injected into the hippocampus of 7-month-old 3xTg-AD mice and the mice were analyzed at 18 months of age. Results: Our findings demonstrated that amyloid seeds from the human patient have more capacity to generate Aβ plaques vs seeds from aged 3xTg-AD mice. Conclusions: These results suggest that seeds from human patients seem to be more amyloidogenic than from aged 3xTg-AD mice. Thus, more profound understanding these factors will provide key insight on how amyloid pathology progress in AD.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tec
Impact of white adipose tissue in AD pathology
Introduction: Alzheimer’s disease (AD) is a complex disorder and multiple cellular and molecular mechanisms are involved in AD onset and progression. Recent evidences has suggested that metabolic alterations are an important pathological feature in disease progression in AD. Likewise, diabetes and obesity, two mayor metabolic illnesses, are risk factors for AD. In addition, novel studies has suggested that AD induces peripheral metabolic alterations, facilitating the development of diabetes. Overall, these studies suggest that there is an important two-way crosstalk between AD and peripheral metabolic disorders. Here, we seek to understand the mechanisms underlying this association and we hypothesize that the white adipose tissue may serve as a key communicator organ between the brain and peripheral metabolic illnesses and alterations in this organ may affect both types of disorders.
Methods: Here, we used histological stains, immunohistochemistry and biochemical means to determine changes in the white adipose tissue from wt and 3xTg-AD mice. Moreover, similar techniques were used in the brain of 3xTg-AD mice that received white fat pads from wt and 3xTg-AD donors to determine any changes in amyloid and tau pathology.
Results: Our study shows that 3xTg-AD mice develop significant peripheral metabolic alterations which in turn affected the white adipose tissue biology. Moreover, adipose tissue transplanted from donor 3xTg-AD and wt mice into recipient 3xTg-AD mice indicate that AD associated white fat tissue induced profound AD pathology changes in recipient 3xTg-AD mice.
Conclusions: Overall, our study demonstrate a novel important crosstalk between AD and peripheral metabolic disorders thought white adipose cells. A more profound understanding in these processes may turn in novel and promising therapeutic strategies for AD and metabolic illnesses.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
Amyloid propagation in a sporadic model of Alzheimer disease
Most age-associated neurodegenerative disorders involve the aggregation of
specific proteins within the nervous system, as occurs in Alzheimer’s disease (AD). Recent
evidence indicates that Aβ can misfold and aggregate into seeds that structurally corrupt
native proteins, mimicking a prion-like process of template protein corruption or seeding. In
fact, studies in FAD-based animal models show that Aβ deposition and cerebral amyloid
angiopathy may be induced by intracerebral infusion of brain extracts from AD patients or
from aged APP-transgenic mice. These studies have shown that the characteristic of both
the seeding agent and the host influence the pathologic signature of the Aβ seeds. In this
regard, the majority of the Aβ-seeding studies have been done in APP-transgenic animal
models that overproduce APP and/or Aβ. However, it remains to be elucidated whether Aβ
deposition can be induced by Aβ seeds in an animal model that does not overexpress APP
and produces wild type human Aβ and if these aggregates are similar to the human
condition.
Here, we used an innovative animal model to better understand the
amyloidogenic events that occur in the sporadic form of the disease. Our model, termed
hAβ-KI, expresses wild-type human Aβ under the control of the endogenous mouse APP
gene. Thus, amyloid seeds from AD patients (stage C for amyloid) from the Alzheimer’s
Disease Research Center (ADRC) at UCI were administered into 7-8-month-old hAβ-KI and
as positive controls 3xTg-AD mice were employed.
Our findings demonstrated that amyloid seeds differentially occur in 3xTg-AD and
hAb-KI mice and these aggregates are developed earlier in the familial model, 3xTg-AD
mice.
These results suggest that multiple factors such as the seed, recipient model
and time are critical factors that can modulate the amyloid pathology onset and
progression. Thus, more profound understanding these factors will provide key insight on
how amyloid pathology progress in AD.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech
The importance of strigolactone transport regulation for symbiotic signaling and shoot branching
Identificação espécie-específica de carnes e produtos cárneos de origem bubalina e bovina pela técnica de PCR-RFLP
Ecological relevance of strigolactones in nutrient uptake and other abiotic stresses, and in plant-microbe interactions below-ground
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
BACKGROUND:
Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes.
METHODS:
We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization.
RESULTS:
During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events.
CONCLUSIONS:
Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)
- …